近年来发展抗血吸虫新药的进展  

Progress in Development of New Antischistosomal Drugs in Recent Years

作　　者：肖树华[1] 

机构地区：[1]中国疾病预防控制中心寄生虫病预防控制所,卫生部寄生虫病原与媒介生物学重点实验室,世界卫生组织疟疾,血吸虫病和丝虫病合作中心,上海200025

出　　处：《中国寄生虫学与寄生虫病杂志》2010年第3期218-225,共8页Chinese Journal of Parasitology and Parasitic Diseases

摘　　要：全球有2亿人感染血吸虫,其治疗仅依赖吡喹酮一种药物是很不相适应的。吡喹酮虽有很好的治疗效果,但无预防作用,故发展抗血吸虫新药倍受关注。本文综述近年来报道的恶二唑-2-氧化物和甲氟喹等抗血吸虫新药的实验研究,阐述这些药物的发展过程,及其抗血吸虫特点。It is estimated that 200 million people have suffered the infection with schistosomes in the world. The fact that treatment of schistosomiasis only relies on a single drug praziquantel does not adapt to the demand. Although praziquantel exhibits excellent therapeutic efficacy, it shows no preventive action to the infection. Therefore, development of new anti-schistsomal drugs has been received serious attention. In this paper the recent development of new antischistosomal drugs such as oxadiazole-2-oxides, mefloquine, etc. has been reviewed, and the process of their development and anti-schistosomal properties recounted.

关 键 词：血吸虫 血吸虫病 恶二唑-2-氧化物 甲氟喹 吡喹酮 

分 类 号：R382.312[医药卫生—医学寄生虫学]